Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance-Reference-Cited by-同舟云学术

Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance

Published:2020-11-01 Issue:3 Volume:85 Page:363-371
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Acosta Rima K.,Willkom Madeleine,Andreatta Kristen,Liu Hui,Martin Ross,Parvangada Aiyappa,Martin Hal,Collins Sean,White Kirsten L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference38 articles.

1. The end of AIDS: HIV infection as a chronic disease;Deeks;Lancet,2013

2. Life expectancy living with HIV: recent estimates and future implications;Nakagawa;Curr Opin Infect Dis.,2013

3. Demographics of HIV and aging;Costagliola;Curr Opin HIV AIDS.,2014

4. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I;Andreatta;J Antimicrob Chemother.,2019

5. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel;Saag;JAMA,2018

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching Human Immunodeficiency Virus Therapy;Infectious Disease Clinics of North America;2024-09

2. Clinical considerations when switching antiretroviral therapy;Expert Review of Clinical Pharmacology;2024-06-17

3. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net);HIV Medicine;2024-06-10

4. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis;Journal of Antimicrobial Chemotherapy;2024-05-17

5. HIV-1 Resistance Analysis of Participants With HIV-1 and Hepatitis B Initiating Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide or Dolutegravir Plus Emtricitabine/Tenofovir Disoproxil Fumarate: A Subanalysis of ALLIANCE Data;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-04-23